Scholarlink

<p><i>Naja atra</i> venom induces severe myotoxicity and inflammation largely driven by snake venom phospholipase A<sub>2</sub> (SVPLA<sub>2</sub>). Although the SVPLA<sub>2</sub> inhibitor varespladib shows great therapeutic promise, the underlying molecular mechanisms remain unclear. Herein, we uncover dual pathogenic pathways. First, a translational module in which RPL35A interacts with PTBP1 to selectively enhance IL-6 and TNF-α translation without altering mRNA levels. Second, a transcriptional axis where prostaglandin E2–activated p38 MAPK enhances NF-κB signaling and reactive oxygen species production, forming an inflammatory-oxidative cycle. Notably, AAV9–mediated RPL35A knockdown in the mouse gastrocnemius reduces inflammation and tissue injury, with combined p38 inhibition providing synergistic protection in vivo, and similar effects are observed in vitro. Taken together, this study reveals that SVPLA<sub>2</sub> drives pathology via coordinated transcriptional and translational mechanisms, supports varespladib’s therapeutic potential, and unveils a non-canonical pro-inflammatory role of RPL35A beyond its ribosomal function, which offers therapeutic possibilities for the treatment of other inflammatory diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chinese cobra (Naja atra) SVPLA2 promotes muscle inflammation via RPL35A-mediated translational reprogramming

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月17日

查看全文
  • Jiahao Liu,
  • Yiqin Zeng,
  • Zejing Wen,
  • Sunkun Tang,
  • Qian Li,
  • Jiaqi Sun,
  • Yuji Jin,
  • Xiaowen Bi,
  • Yang Yang,
  • Chunhong Huang

摘要

Naja atra venom induces severe myotoxicity and inflammation largely driven by snake venom phospholipase A2 (SVPLA2). Although the SVPLA2 inhibitor varespladib shows great therapeutic promise, the underlying molecular mechanisms remain unclear. Herein, we uncover dual pathogenic pathways. First, a translational module in which RPL35A interacts with PTBP1 to selectively enhance IL-6 and TNF-α translation without altering mRNA levels. Second, a transcriptional axis where prostaglandin E2–activated p38 MAPK enhances NF-κB signaling and reactive oxygen species production, forming an inflammatory-oxidative cycle. Notably, AAV9–mediated RPL35A knockdown in the mouse gastrocnemius reduces inflammation and tissue injury, with combined p38 inhibition providing synergistic protection in vivo, and similar effects are observed in vitro. Taken together, this study reveals that SVPLA2 drives pathology via coordinated transcriptional and translational mechanisms, supports varespladib’s therapeutic potential, and unveils a non-canonical pro-inflammatory role of RPL35A beyond its ribosomal function, which offers therapeutic possibilities for the treatment of other inflammatory diseases.